Komal Jhaveri, MD, FACP - Dialing Up Precision in HR+, HER2- MBC With New Endocrine Agents, Targeted Therapies, and Combinations: A Framework for Multifactorial Clinical Decisions

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NXT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until January 15, 2027.Dialing Up Precision in HR+, HER2- MBC With New Endocrine Agents, Targeted Therapies, and Combinations: A Framework for Multifactorial Clinical Decisions In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Genentech, a member of the Roche Group, Lilly, and Stemline Therapeutics, a Menarini Company Group.Disclosure information is available at the beginning of the video presentation.